SABCS 2023 HR+/HER2-

Primary Analysis of HER2CLIMB-02: Addition of Tucatinib to Trastuzumab Emtansine in Previously Treated Patients with HER2-Positive Metastatic Breast Cancer

Video Library —February 8, 2024

Categories:

Rapid Reactions
Sara M. Tolaney, MD, MPH
Chief, Division of Breast Oncology, Dana-Farber Cancer Institute
Associate Professor of Medicine, Harvard Medical School
Boston, MA
Dr Tolaney of Dana-Farber Cancer Institute reviews data on HER2CLIMB-02 and contributes future considerations of tucatinib in the metastatic HER2-positive breast cancer setting.
Related Articles
Real-world Outcomes Following Initiation of Abemaciclib in Patients With Brain Metastases Secondary to HR+/HER2- Metastatic Breast Cancer
Hope S. Rugo, MD
|
Video Library
Dr Rugo of the University of California San Francisco Comprehensive Cancer Center reports on the outcomes of a retrospective study of patients with metastatic breast cancer and brain metastases treated with abemaciclib.
INAVO120 Phase III Study: Treatment of Patients With PIK3CA-mutant, HR+/HER2- Locally Advanced or Metastatic Breast Cancer With Invavolisib in Combination With Palbociclib and Fulvestrant
Hope S. Rugo, MD
|
Video Library
Dr Rugo of the University of California San Francisco Comprehensive Cancer Center provides her insights on the practical aspects of the reported results of the INAVO120 phase 3 study.
Abemaciclib and NSAI for 1L Treatment of HR+/HER2- Advanced Breast Cancer: Long-term Survival Data Reported
Sara M. Tolaney, MD, MPH
|
Video Library
Dr Tolaney of Dana-Farber Cancer Institute discusses her perspectives on the clinically meaningful overall survival outcomes of abemaciclib added to a nonsteroidal aromatase inhibitor as initial therapy in patients with HR+/HER2- advanced breast cancer.
Last modified: February 5, 2024

Subscribe Today!

To sign up for our print publication or e-newsletter, please enter your contact information below.

I'd like to receive:

  • First Name *
    Last Name *
     
     
    Profession or Role
    Primary Specialty or Disease State
    Country
SUBSCRIBE

Contact Us | Editorial Board

© 2009- DBA AONN+ Academy of Oncology Nurse & Patient Navigators® PO Box 563, Cranbury, NJ 08512